Asset Details
Do you wish to reserve the book?
Lev Pharmaceuticals Announces Initiation of Phase III Clinical Trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Lev Pharmaceuticals Announces Initiation of Phase III Clinical Trial
Do you wish to request the book?
Lev Pharmaceuticals Announces Initiation of Phase III Clinical Trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Newsletter
Lev Pharmaceuticals Announces Initiation of Phase III Clinical Trial
2005
Overview
LevPharma is developing its C1-INH product through an agreement with Sanquin Blood Supply Foundation (\"Sanquin\"), an Amsterdam-based not-for-profit organization that provides blood and plasma products and related services, carries out research and provides education, primarily in the Netherlands. Sanquin has been producing and selling successive generations of C1-INH, prepared from human plasma, in the Netherlands for over 30 years for the treatment of HAE. Continuous product development efforts at Sanquin have resulted in the current, highly purified product which has been marketed since 1997. Despite its long record of use in Europe, however, C1-INH, has never been introduced in the United States. Through a supply and distribution agreement with Sanquin, LevPharma has the exclusive right to market and sell C1-INH prepared by Sanquin for the treatment of HAE in North America and certain other geographic regions. LevPharma is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. LevPharma's product candidates are based on C1-esterase inhibitor (\"C1-INH\"), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. In addition to the treatment of hereditary angioedema, LevPharma is also developing C1-INH for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role.
Publisher
Business Wire
